Literature DB >> 9057669

CD34+ cells in the blood of patients with multiple myeloma express CD19 and IgH mRNA and have patient-specific IgH VDJ gene rearrangements.

A J Szczepek1, P L Bergsagel, L Axelsson, C B Brown, A R Belch, L M Pilarski.   

Abstract

Peripheral blood mononuclear cells (PBMC) from patients with multiple myeloma (MM) are here shown to include 23% +/- 2% of CD34+ cells, the majority of which coexpress CD19, as identified by a panel of 17 anti-CD34 antibodies. The expression of CD34 mRNA by sorted CD34+ PBMC from MM was confirmed by in situ reverse transcriptase-polymerase chain reaction (RT-PCR) with CD34-specific primers. The majority of CD34+ MM PBMC were CD19+ cells that expressed mRNA for CD19 and for rearranged IgH as identified with consensus IgH VDJ primers, as well as having cytoplasmic Ig, definitively identifying them as B cells, in absolute numbers of 0.06 to 0.69 x 10(9)/L of blood. CD34 is largely absent from normal B cells. To determine the clonal relationship of CD34+ B cells to autologous MM plasma cells, IgH VDJ DNA rearrangements of sorted CD34+ MM blood B cells were amplified by nested PCR using consensus primers followed by Southern blotting with allele-specific oligonucleotides for 7 MM patients, and clonotypic IgH mRNA expression was assessed for 4 MM patients using quantitative patient-specific in situ RT-PCR. For 9 of 11 myeloma patients tested, CD34+ blood B cells included IgH gene rearrangements or expressed IgH mRNA identical to that of autologous bone marrow plasma cells. For 4 of 4 MM patients, 74% to 94% of individual sorted CD34+19+ B cells expressed clonotypic IgH mRNA, as detected by in situ RT-PCR with patient-specific primers. Clonotypic IgH VDJ sequences were absent from B cells of unrelated MM patients and of normal donors. Clonotypic CD34+ B cells were detected before, during, and after treatment, and during relapse. Our results indicate a clonal relationship between CD34+ MM B cells and malignant plasma cells. We speculate that CD34 may play an important role in the biology of myeloma by facilitating extravasation from blood and thus spread of myeloma through the skeletal system.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9057669

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Novel analysis of clonal diversification in blood B cell and bone marrow plasma cell clones in immunoglobulin light chain amyloidosis.

Authors:  Roshini S Abraham; Michelle K Manske; Neta S Zuckerman; Abhishek Sohni; Hanna Edelman; Gitit Shahaf; Michael M Timm; Angela Dispenzieri; Morie A Gertz; Ramit Mehr
Journal:  J Clin Immunol       Date:  2006-12-28       Impact factor: 8.317

Review 2.  Multiple myeloma: increasing evidence for a multistep transformation process.

Authors:  M Hallek; P L Bergsagel; K C Anderson
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

3.  Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells.

Authors:  Alicia Báez; José I Piruat; Teresa Caballero-Velázquez; Luís I Sánchez-Abarca; Isabel Álvarez-Laderas; M Victoria Barbado; Estefanía García-Guerrero; África Millán-Uclés; Jesús Martín-Sánchez; Mayte Medrano; José Antonio Pérez-Simón
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

4.  Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.

Authors:  Sophia Adamia; Tony Reiman; Mary Crainie; Michael J Mant; Andrew R Belch; Linda M Pilarski
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

5.  TP53 mutations coincide with the ectopic expression of activation-induced cytidine deaminase in the fibroblast-like synoviocytes derived from a fraction of patients with rheumatoid arthritis.

Authors:  H Igarashi; J Hashimoto; T Tomita; H Yoshikawa; K Ishihara
Journal:  Clin Exp Immunol       Date:  2010-05-10       Impact factor: 4.330

6.  Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus.

Authors:  Eric Bartee; Winnie M Chan; Jan S Moreb; Christopher R Cogle; Grant McFadden
Journal:  Biol Blood Marrow Transplant       Date:  2012-04-16       Impact factor: 5.742

7.  CD34+ myeloma cells with self-renewal activities are therapy-resistant and persist as MRD in cell cycle quiescence.

Authors:  Kentaro Serizawa; Hirokazu Tanaka; Takeshi Ueda; Ayano Fukui; Hiroaki Kakutani; Takahide Taniguchi; Hiroaki Inoue; Takahiro Kumode; Yasuhiro Taniguchi; Shinya Rai; Chikara Hirase; Yasuyoshi Morita; J Luis Espinoza; Yoichi Tatsumi; Takashi Ashida; Itaru Matsumura
Journal:  Int J Hematol       Date:  2022-02-08       Impact factor: 2.490

Review 8.  The rise and fall of long-lived humoral immunity: terminal differentiation of plasma cells in health and disease.

Authors:  Brian P O'Connor; Michael W Gleeson; Randolph J Noelle; Loren D Erickson
Journal:  Immunol Rev       Date:  2003-08       Impact factor: 12.988

9.  Stemness of B-cell progenitors in multiple myeloma bone marrow.

Authors:  Kelly Boucher; Nancy Parquet; Raymond Widen; Kenneth Shain; Rachid Baz; Melissa Alsina; John Koomen; Claudio Anasetti; William Dalton; Lia E Perez
Journal:  Clin Cancer Res       Date:  2012-09-17       Impact factor: 12.531

10.  Reovirus as a successful ex vivo purging modality for multiple myeloma.

Authors:  C M Thirukkumaran; Z Q Shi; J Luider; K Kopciuk; N Bahlis; P Neri; M Pho; D Stewart; A Mansoor; D G Morris
Journal:  Bone Marrow Transplant       Date:  2013-08-26       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.